Kornimate/medical-research-clean huggingface dataset:
early detection of breast cancer using tomosynthesis imaging

Conditions: Breast Neoplasms

Summary: the purpose is to develop digital tomosynthesis to improve the detection of breast cancers. the aims are optimizing digital mammography and tomosynthesis acquisition, creating visualization tools, prospective pilot studies to evaluate radiologist performance, and computer-aided detection.

finding breast cancer early has been shown to improve the chance of survival. mammography (x-ray imaging of the breast) helps find breast cancer early. some breast cancers, however, are not seen on mammography, which creates two-dimensional images for the radiologist to see. the goal of this study is to make a breast tomosynthesis or tomosynthesis 3d (three-dimensional) x-ray system by taking x-ray images from many angles. this is similar to a cat (computerized axial tomography) scan for the breast and can give radiologists 3d information so that they can find breast cancers which might otherwise be hidden from view.

Eligibility criteria:
inclusion criteria: all subjects accepted for this clinical study must: * be already scheduled to undergo screening mammography, diagnostic mammography, or breast biopsy for standard clinical indications * provide written informed consent * be able to communicate effectively with clinical study personnel. exclusion criteria: subjects with any of the following conditions will be excluded from this clinical study: * childbearing potential and subject refuses serum pregnancy test or test result is positive.

Keywords: diagnostic imaging mammography breast tomosynthesis
structural modification in supraglottic airway device

Conditions: Airway Complication of Anesthesia; Ventilation Therapy; Complications; Hypoxia; Hypoventilation

Summary: the proposed a/z modification of a supraglottic airway (sga) incorporates an opening in the sga body that enables access to the endotracheal tube (ett) through the body of the sga without the need of using an exchange catheter, thus enabling an ett to move in the body of the sga and convert a supraglottic to endotracheal ventilation. in its original form an adaptor made from same material currently used in the endotracheal tubes can make ventilation through the proposed airway device possible in exactly the same manner of a conventional sga currently used. this adapter also known as the r-piece can be replaced with an ett. the modification also allows placement of sga over an existing ett to convert and endotracheal (et) to supraglottic (sg) mode of ventilation without the need to use an exchange catheter.

the special design allows conversion of a telescopic coaxial portion (r piece), replacing with an ett which can act coaxially to provide both supraglottic (up position) and endotracheal (down position) of ett. see this modification in https://www.youtube.com/watch?v=iy84lalu1ai currently the proposed change to the conventional sga has been made and feasibility tested on manikins. the a/z airway modification is also demonstrated in the attached link video https://www.youtube.com/watch?v=ukloac55ig8 in this study, we are trialing the a/z concept on an original a/z modification by a manufacturer on their currently used sga. thus instead of investigators making the changes by cutting a channel in a conventional sga immediately before use in the operating room, they have asked a manufacturer to do so professionally.

Eligibility criteria:
inclusion criteria: 1. adult patients 2. scheduled for a general anesthesia procedure with ett \& muscle relaxation exclusion criteria: 1. patients who are not able to consent 2. non english speaking 3. history of difficult airway 4. physical exam of airway which suggests difficulty in airway management or need to use special equipment 5. bmi \>35 6. gastroesophageal reflux disease 7. anesthetic plan other than general anesthesia 8. emergency procedures

Keywords: airway management oxygenation and ventilation airway devices supraglottic airway
tumor registry of lymphatic neoplasia

Conditions: Non-Hodgkin's Lymphoma (NHL); Chronic Lymphocytic Leukemia (CLL); Multiple Myeloma (MM)

Summary: the purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in germany.

the tln is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of lymphatic neoplasms in germany. the registry will follow patients for up to five years. it will identify common therapeutic sequences and changes in the treatment of the disease. at inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. during the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. the impact of nutrition (lynut) and physical activity (lynut) on the course of the adjuvant disease will be examined in patients with indolent and aggressive non-hodgin lymphoma, as well as long-term effects of systemic treatment (lytox) and quality of life (lylife) in patients with multiple myeloma.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of non-hodgkin's lymphoma, chronic lymphocytic leukaemia or multiple myeloma * must receive a first- or second-line therapy * 18 years or older * signed, written informed consent exclusion criteria: - no systemic therapy

Keywords: malignant lymphatic disease therapy-reality observation registry therapy sequences nhl cll germany lenalidomide alemtuzumab rituximab bendamustin thalidomide bortezomib ibritumomab-tiuxetan g-csf (granulocyte-colony stimulating factor) chronic lymphocytic leukaemia follicular lymphoma gastric malt lymphoma (mucosa associated lymphoid tissue) nongastric malt lymphoma (mucosa associated lymphoid tissue) nodal marginal zone lymphoma splenic marginal zone lymphoma mantle cell lymphoma diffuse large b-cell lymphoma
cognitive skills training for homeless youth

Conditions: Affective Disorders; Anxiety Disorders; Attention Deficit Disorder; Substance Abuse

Summary: many young people who are homeless have cognitive deficits which impede their ability to secure and maintain employment. this study looks to see if targeting cognitive deficits can improve cognition and vocational outcome.

the aim of this research is to conduct a controlled study of cognitive remediation, to provide feasibility data on adapting an established empirically-based cognitive intervention for homeless youth to help them attain vocational goals. the ultimate purpose is that youth will improve in cognitive functioning and have better functional outcomes including jobs to sustain independent living. the results of this study will inform a larger trial on the efficacy of cognitive remediation in homeless youth to improve cognition and vocational outcomes. hypotheses are that, compared to those in an active control group receiving computerized work-skills training, individuals who receive cognitive remediation will show greater cognitive benefits on proximal measures of neurocognition and evidence better vocational outcome as defined by greater number of hours worked. this study will address the service gap in the use of integrated psychosocial interventions for homeless populations as the first investigation of cognitive remediation in homeless youth.

Eligibility criteria:
inclusion criteria: * have a current diagnostic and statistical manual (dsm-iv) axis i diagnosis * residing at covenant house new york rights of passage program * psychiatrically stable for at least 21 days * english speaking exclusion criteria: * mental retardation (\<70 intelligence quotient; iq) on premorbid intelligence estimate) * risk for suicide or violence * unremitted substance dependence within the past 6 weeks
assessing the minimal important difference (mid) of the treatment related impact measure-adult growth hormone deficiency (trim-aghd)

Conditions: Growth Hormone Disorder; Adult Growth Hormone Deficiency

Summary: this study is conducted in the united states of america (usa). the aim of the study is to assess the minimal important difference (mid) of the trim-aghd.


Eligibility criteria:
inclusion criteria: * able to speak read and write english * ghd (growth hormone deficiency) treatment naïve which is defined as not being on a prescription treatment for their ghd currently and for at least 6 months * beginning a new prescription ghd treatment and expected to be on this treatment for ghd for a minimum of 6 months * ghd of either one of the following criteria: a) adult onset: subjects who have ghd, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or traumatic brain injury (tbi), b) childhood onset: subjects who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes * confirmed diagnosis of growth hormone deficiency (if a subject satisfies any one of the three following criteria): a) for the insulin tolerance test (itt) or glucagon test both performed within the last five years: the validated cut-off for ghd in adults is a peak gh response of below 3.0 ng/ml (3 microg/l), b) for growth hormone releasing hormone (ghrh) +arginine test performed within the last five years: for those subjects with a body mass index (bmi) below 25 kg/m\^2, a peak gh below 11 ng/ml (microg /l); for bmi 25-30 kg/m\^2, a peak gh below 8 ng/ml (8 microg/l); for bmi above 30 kg/m\^2, a peak gh below 4 ng/ml 341 (4 microg/l ), c) three or more pituitary hormone deficiencies at screening * informed consent obtained before any study-related activities. (study-related activities are any procedure related to recording of data according to the protocol) exclusion criteria: * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * patients who have been on a prescription medication for treatment of ghd in past 6 months * patients with a total beck depression inventory ii (bdi-ii) score greater than 25 * females who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) * acute severe illness associated with weight loss in the last 6 months (defined as a loss of more than 5.0% total body weight) * active cushings syndrome within the last 24 months * subject with overt diabetes mellitus * previous participation in this study
effect of thoracic block technique on arterial blood gases in children with atelectasis on mechanical ventilation

Conditions: Atelectasis; Intensive Care Unit; Children

Summary: statement of the problem: • does the thoracic block technique has effect on arterial blood gases, vital signs and lung compliance in children with atelectasis on mechanical ventilation? null hyposis there is no effect of thoracic block technique on arterial blood gases, vital signs and lung compliance in children with atelectasis on mechanical ventilation.

subjects: the study targets the children from both sexes.diagnosed with atelectasis in intensive care unit. sample size estimation will be carried out to determine the recruited number of children, selected randomly from cairo university pediatric specialized hospital, cairo to participate in the study, study design: randomized controlled clinical trial. children will receive intervention type randomly, 22 child received percussion, vibration, modified postural drainage and the other 22 child will receive percussion, vibration, modified postural drainage and thoracic block technique. children will be assessed by measuring heart rate, respiratory rate,which reflect the physiological status, arterial blood gases which include partial pressure of oxygen (pao2), partial pressure of carbon dioxide (paco2) and oxygen saturation (sao2) and dynamic lung compliance which reflect clinical improvement of chest condition before and after ten days of receiving intervention

Eligibility criteria:
inclusion criteria: 1. age range from 4 months to 4 years. 2. diagnosed with pneumonia, receiving mechanical ventilation. 3. start from second day of admission to intensive care unit 4. have unilateral mild to moderate atelectasis according to medical referral. 5. should be vitally stable during the session. exclusion criteria: the children were excluded from the study if they had one of the following: 1. medically unstable ( examples: tachycardia and tachypnea) 2. uncontrolled convulsion. 3. rib fracture. 4. pneumothorax -
a triple-targeted cell preparation targeting cd19/cd20/cd22 in patients with relapsed/refractory b-cell acute lymphocytic leukemia

Conditions: Acute Lymphocytic Leukemia

Summary: a phase i, open-label clinical study to evaluate the safety, tolerability, and efficacy of lcar-aio, a triple-targeted cell preparation targeting cd19/cd20/cd22, in patients with relapsed/refractory b-cell acute lymphocytic leukemia

this is an open-label, dose escalation/expansion study to assess the safety, tolerability, and efficacy of lcar-aio in patients ≥ 18 years of age with relapsed or refractory b-cell acute lymphocytic leukemia. patients who meet the eligibility criteria will receive a single dose of lcar-aio infusion. the study will include the following sequential phases: screening, pre-treatment (cell product preparation; lymphodepleting chemotherapy), treatment and follow up.

Eligibility criteria:
inclusion criteria: 1. subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures, and have signed informed consent; 2. age 18-75 years; 3. ecog score: 0-1; 4. detect the expression of at least one of cd19/cd20/cd22 in leukemic cells by flow cytometry in peripheral blood or bone marrow 5. leukemia cells in the bone marrow \>5% 6. pathologically confirmed relapsed/refractory all must meet one of the following conditions: 1. naive patients who failed to achieve cr1 after standard chemotherapy; 2. relapse within 12 months after cr1, or relapse after 12 months but fail to achieve cr2 3. twice or more bone marrow relapse 4. philadelphia chromosomal positive (ph+) and unable to tolerate tki therapy, failed tki therapy more than 2 lines, or had contraindications for tki therapy 7. clinical laboratory values meet screening visit criteria 8. expected survival ≥ 3 months; exclusion criteria: 1.prior antitumor therapy with insufficient washout period; 2.cns infiltration; except for patients with prior cns infiltration who are currently in remission; 3.have received two or more targets (cd19/cd20/cd22) car-t cell therapy (including but not limited to sequential infusion) at any previous time, or have received car-t cell therapy from camel family origin; 4.with acute or chronic graft-versus-host disease; 5.isolated extramedullary relapse, but hepatic, spleen, or lymph node-isolated extramedullary relapse is acceptable; 6.hbsag, hbv dna, hcv-ab, hcv rna or hiv-ab positive; 7.pregnant or lactating women; -
personality traits and exercise addiction in ultra endurance athletes

Conditions: Exercise Addiction

Summary: ultra endurance sports (events exceeding 6 hours) is becoming increasingly popular and exercise addiction (ea) is frequent in this type of sports, which are characterized by very high training volume. however, little is known about the personality traits of athletes who are more likely to develop ea. this study aims to assess the personality traits associated with ea in ultra endurance athletes. we designed a cross sectional study. participants have to fill a web-based questionnaire including the big five personality test for assessing the personality traits and the exercise dependence scale-revised (eds-r) for assessing ea. also they have to fill a personal question about demographics (age, gender, work), sport practice and eating habits. a minimum sample size of 300 participants is expected. statistical analyses will test the association between personality traits and the presence (or absence) of ea according to the eds-r. secondary analysis will test the association between the type of sport (running, cycling, triathlon, swimming), the volume of sport practice and the presence of eating disorders and ea.


Eligibility criteria:
inclusion criteria: * athletes participating in ultra endurance sport events (exceeding 6 hours) in running/trail, cycling, swimming, nordic skiing * individuals who volunteered to participate in the study * individuals with access to internet * individuals reading french exclusion criteria: * individuals not meeting the inclusion criterias * individuals who did not participate in an ultra endurance event in the previous year
treatment of anal fistula with lasercoagulation

Conditions: Fistula-In-Ano; Anal Fistula

Summary: the purpose of this study is to determine whether treatment with laser coagulation is an effective and safe treatment option for patients with anal fistula

treatment of anal fistula remains a challenge - the only truly effective treatment available (fistulotomy) involves very high rates of anal incontinence if performed on the majority of patients, and a vast number of alternative, sphincter-preserving treatments have been developed and evaluated in the past decades. the treatment of anal fistula with laser coagulation causes the fistula to collapse and subsequently heal, without having to add any external materials. the available published studies show that the treatment is safe regarding infection and incontinence, and that a majority of the patients treated show complete healing. there is however a need for more prospective studies to ascertain these preliminary facts.

Eligibility criteria:
inclusion criteria: 1. subject has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent. 2. subject must be at least 18 years of age 3. subject must have a verified anal fistula (by transanal ultrasound performed by treating surgeon) 4. subject must have a clean and infection-free fistula tract (no cavities seen on transanal ultrasound) 5. subject must be able to comply with study and study follow-up requirements. exclusion criteria: 1. subject with anorectal fistula due to crohn's disease 2. subject has an undrained abscess in fistula tract (cavities as seen on transanal ultrasound) 3. subject has fistula with side tracts (as seen on transanal ultrasound) 4. subject is unable or unwilling to provide informed consent.

Keywords: filac fistula laser closure laser coagulation
bacterial colonization in copd in view of cat under ics+laba therapy

Conditions: Bacterial Infections; Chronic Obstructive Pulmonary Disease; Self-Assessment

Summary: patients with copd (chronic obstructive pulmonary disease) suffer from episodes of acute exacerbations leading to additional morbidity and mortality, and also a further decline in lung function. it has been well-established that bacterial colonization is prevalent in copd, especially in moderate to severe copd, and airway bacterial colonization is known to play an important role in the development of pneumonia and exacerbations. on the other way, inhaled corticosteroid (ics) and long acting β2 agonist (laba) were recommended in the treatment of moderate to severe copd. though there were some evidences that ics had some protective effects on airway mucosa against bacteria invasion, the locally immunosuppressive effects of ics is still a concern. indeed, the incidence of pneumonia was higher than the control group, not only in the towards a revolution in copd health (torch) study but also in various studies and meta-analyses.we hypothesized that airway bacteria colonization is associated with disease severity, and that disease status can be identified by cat (copd assessment test)scores and changes of cat scores. we therefore conducted this prospective, observational study in which cat scores and sputum cultures were assessed in moderate to severe copd patients with the combination therapy of ics and laba every three months during the study period. the primary end-point is the condition of potential pathogenic microorganisms (ppm) colonization in view of cat scores. the second end-point was the changes of ppm colonization in association with cat changes during follow-up. by the mean of cat follow-up, it could possibly provide a surrogate about the risk of exacerbation and pneumonia under the combination therapy of ics and laba.


Eligibility criteria:
inclusion criteria: * spirometry showed obstructive ventilatory defect (a ratio of forced expiratory volume in one second (fev1) to forced vital capacity (fvc) of less than 0.7) and fev1 less than 80% of predicted value and patients receiving the combination therapy of ics and laba exclusion criteria: * (1) use of antibiotics or corticosteroids within eight weeks before study entry; (2) pneumoconiosis; (3) apparent inactive tuberculosis fibrosis (fibrosis involved in more than one third of one lung field as determined by chest radiography); and (4) asthma and atopic history.